Literature DB >> 9458982

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

C Thornsberry1, P Ogilvie, J Kahn, Y Mauriz.   

Abstract

A U.S. surveillance study of antimicrobial resistance in respiratory tract pathogens in the respiratory season (1996-1997) is reported that included 11,368 isolates from 434 institutions in 45 states and the District of Columbia. beta-lactamase was produced by 33.4% of Haemophilus influenzae and 92.7% of Moraxella catarrhalis. Of the 9,190 Streptococcus pneumoniae isolates tested, 33.5% were not susceptible to penicillin (MIC > or = 0.12 microgram/mL), with 13.6% having high-level resistance (MICs > 1 microgram/mL). For H. influenzae, the most active antimicrobials (based on percent of strains susceptible) were levofloxacin (100%) and ceftriaxone (99.9%); the least active were ampicillin (67.2%) and clarithromycin (58.1%). For M. catarrhalis, the most active drugs were amoxicillin-clavulanate, ceftriaxone, and levofloxacin (100%); the least active was ampicillin. The order of the activity of the drugs against S. pneumoniae were levofloxacin (97.3%) > ceftriaxone (87.1%) > amoxicillin-clavulanate (81.7%) = clarithromycin (80.9%) > cefuroxime (74.5%) > penicillin (66.5%). The activity of the beta-lactams and clarithromycin against isolates of S. pneumoniae was closely associated with the resistance to penicillin. Levofloxacin was more active against S. pneumoniae overall, because it exhibited no cross-resistance. These data indicate that the incidence of beta-lactamase production in H. influenzae (33.4%) and M. catarrhalis (92.7%) is similar to other recent studies, and that the incidence of penicillin-intermediate and -resistant S. pneumoniae is increasing, particularly the high-level penicillin-resistant (MICs > 1 microgram/mL) strains, which were often multi-resistant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9458982     DOI: 10.1016/s0732-8893(97)00195-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  44 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 2.  The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults.

Authors:  P J Moss; R G Finch
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

3.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.

Authors:  P L Ho; T L Que; D N Tsang; T K Ng; K H Chow; W H Seto
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  MM1, a temperate bacteriophage of the type 23F Spanish/USA multiresistant epidemic clone of Streptococcus pneumoniae: structural analysis of the site-specific integration system.

Authors:  E Gindreau; R López; P García
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2.

Authors:  J H Jorgensen; A L Barry; M M Traczewski; D F Sahm; M L McElmeel; S A Crawford
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

7.  National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.

Authors:  L D Liebowitz; M Slabbert; A Huisamen
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

8.  Pneumococcal Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

9.  Longitudinal assessment of antipneumococcal susceptibility in the United States.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian A Critchley; Elena Karginova; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model.

Authors:  Myo-Kyoung Kim; Wen Zhou; Pamela R Tessier; Dawei Xuan; Min Ye; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.